Related references
Note: Only part of the references are listed.Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis
Francesco Sacca et al.
EUROPEAN JOURNAL OF NEUROLOGY (2023)
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
James F Howard et al.
LANCET NEUROLOGY (2023)
Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: A systematic review and network meta-analysis
Kaili Chen et al.
FRONTIERS IN AGING NEUROSCIENCE (2023)
Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease
George J Kahaly et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)
Efgartigimod: First Approval
Young-A Heo
DRUGS (2022)
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis The BeatMG Study
Richard J. Nowak et al.
NEUROLOGY (2022)
Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases
Panos Stathopoulos et al.
NEUROTHERAPEUTICS (2022)
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals
Deepak Menon et al.
DRUGS (2022)
Eculizumab versus rituximab in generalised myasthenia gravis
Christopher Nelke et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)
Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options
Rachel Zeng et al.
NEUROTHERAPEUTICS (2022)
Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study
Chong Yan et al.
NEUROLOGY AND THERAPY (2022)
The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis
Jeffrey A Tice et al.
Journal of Managed Care & Specialty Pharmacy (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial
James F. Jr Jr Howard et al.
LANCET NEUROLOGY (2021)
Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis
Sanjiv Bastakoti et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2021)
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial
James F. Howard et al.
JAMA NEUROLOGY (2020)
Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics
Konstantinos Lazaridis et al.
FRONTIERS IN IMMUNOLOGY (2020)
CINeMA: An approach for assessing confidence in the results of a network meta-analysis
Adriani Nikolakopoulou et al.
PLOS MEDICINE (2020)
Monoclonal Antibody-Based Therapies for Myasthenia Gravis
Sawsan Alabbad et al.
BIODRUGS (2020)
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
James F. Howard et al.
NEUROLOGY (2019)
Myasthenia gravis
Nils Erik Gilhus et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics
Christopher J. Patriquin et al.
TRANSFUSION MEDICINE REVIEWS (2019)
Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia A Network Meta-analysis
Ismaeel Yunusa et al.
JAMA NETWORK OPEN (2019)
B CELLS IN THE PATHOPHYSIOLOGY OF MYASTHENIA GRAVIS
John S. Yi et al.
MUSCLE & NERVE (2018)
Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology
Michael K. Hehir et al.
NEUROLOGIC CLINICS (2018)
Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis
Karen Hewett et al.
NEUROLOGY (2018)
Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration
Bryan Smith et al.
MABS (2018)
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
James F. Howard et al.
LANCET NEUROLOGY (2017)
Facilitation roles and characteristics associated with research use by healthcare professionals: a scoping review
Lisa A. Cranley et al.
BMJ OPEN (2017)
Myasthenia gravis incidence in a general North Atlantic isolated population
P. Joensen
ACTA NEUROLOGICA SCANDINAVICA (2014)
Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4
Jan J. G. M. Verschuuren et al.
AUTOIMMUNITY REVIEWS (2013)
Graphical Tools for Network Meta-Analysis in STATA
Anna Chaimani et al.
PLOS ONE (2013)
B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
Maria J. Leandro
ARTHRITIS RESEARCH & THERAPY (2013)
Automating network meta-analysis
Gert van Valkenhoef et al.
RESEARCH SYNTHESIS METHODS (2012)
ANTI-MuSK ANTIBODY MYASTHENIA GRAVIS: CLINICAL FINDINGS AND RESPONSE TO TREATMENT IN TWO LARGE COHORTS
Jeffrey T. Guptill et al.
MUSCLE & NERVE (2011)
B-Cell-Activating Factor and Autoimmune Myasthenia Gravis
Samia Ragheb et al.
AUTOIMMUNE DISEASES (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Lifetime course of myasthenia gravis
David Grob et al.
MUSCLE & NERVE (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Bayesian measures of model complexity and fit
DJ Spiegelhalter et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2002)